Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Academic Article uri icon

Overview

abstract

  • OBJECTIVE: Subsyndromal major depressive disorder is common among HIV-positive adults. This study was designed to assess the efficacy of dehydroepiandrosterone (DHEA) as a potential treatment. METHOD: One hundred forty-five patients with subsyndromal depression or dysthymia were randomly assigned to receive either DHEA or placebo; 90% (69 of 77) of the DHEA patients and 94% (64 of 68) of the placebo patients completed the 8-week trial. The primary measure of efficacy was a Clinical Global Impression improvement rating of 1 or 2 (much or very much improved) plus a final Hamilton Depression Rating Scale score

publication date

  • January 1, 2006

Research

keywords

  • Adjuvants, Immunologic
  • Dehydroepiandrosterone
  • Depressive Disorder, Major
  • HIV Seropositivity

Identity

Scopus Document Identifier

  • 30044447765

PubMed ID

  • 16390890

Additional Document Info

volume

  • 163

issue

  • 1